Biosimilars: Concept and Regulation

Biosimilars: Concept and Regulation

Copyright: © 2017 |Pages: 18
ISBN13: 9781522507512|ISBN10: 1522507515|EISBN13: 9781522507529
DOI: 10.4018/978-1-5225-0751-2.ch007
Cite Chapter Cite Chapter

MLA

Sharma, Anil K., et al. "Biosimilars: Concept and Regulation." Novel Approaches for Drug Delivery, edited by Raj K. Keservani, et al., IGI Global, 2017, pp. 171-188. https://doi.org/10.4018/978-1-5225-0751-2.ch007

APA

Sharma, A. K., Keservani, R. K., & Kesharwani, R. K. (2017). Biosimilars: Concept and Regulation. In R. Keservani, A. Sharma, & R. Kesharwani (Eds.), Novel Approaches for Drug Delivery (pp. 171-188). IGI Global. https://doi.org/10.4018/978-1-5225-0751-2.ch007

Chicago

Sharma, Anil K., Raj K. Keservani, and Rajesh K. Kesharwani. "Biosimilars: Concept and Regulation." In Novel Approaches for Drug Delivery, edited by Raj K. Keservani, Anil K. Sharma, and Rajesh Kumar Kesharwani, 171-188. Hershey, PA: IGI Global, 2017. https://doi.org/10.4018/978-1-5225-0751-2.ch007

Export Reference

Mendeley
Favorite

Abstract

Biosimilars are a new class of drugs, which are derived from live organism through the recombinant DNA technology. These are recently introduced in the pharmaceutical field for the preparation of drug to prevent or control the diseases. Patients with diabetes and renal failure may already be receiving biosimilar epoetin and may receive same insulin in coming years. The main aim of present article is to introduce the fundamentals of biologics and to explain how they are different and what these differences mean for pharmacists.

Request Access

You do not own this content. Please login to recommend this title to your institution's librarian or purchase it from the IGI Global bookstore.